-4.68 (-100.00%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Genprex Inc | GNPX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 4.68 | 0.00 | 0.00 | 0.00 | 4.68 | 04:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 4.30 | 5.49 | 1.19 | 21.68% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Genprex Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 130.34M | 27.85M | $ -12.37M | -0.89 | - | 27.23M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Genprex News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GNPX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.60 | 7.03 | 3.5859 | 5.53 | 11,423,536 | 0.08 | 1.74% |
| 1 Month | 1.68 | 7.03 | 1.17 | 4.02 | 13,449,201 | 3.00 | 178.57% |
| 3 Months | 0.32 | 7.03 | 0.231 | 2.89 | 7,719,084 | 4.36 | 1,362.5% |
| 6 Months | 0.91 | 7.03 | 0.231 | 2.76 | 3,667,779 | 3.77 | 414.29% |
| 1 Year | 1.45 | 7.03 | 0.231 | 2.75 | 1,863,812 | 3.23 | 222.76% |
| 3 Years | 4.69 | 19.4499 | 0.231 | 3.12 | 1,033,654 | -0.01 | -0.21% |
| 5 Years | 4.69 | 19.4499 | 0.231 | 3.12 | 1,033,654 | -0.01 | -0.21% |
Genprex Description
| Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells. |
